Compass Pathways Research Suggests Psilocybin Can Treat Anorexia

May 12, 2022 12:56:02

Recently released findings from a study show that the psilocybin therapy developed by Compass Pathways PLC (NASDAQ: CMPS) may be used to treat anorexia. The therapy in question, COMP 360, was primarily developed to treat depression. Anorexia or anorexia nervosa is an eating disorder in which individuals have abnormally low weight caused by restricting food intake and an extreme fear of gaining weight.

Psychiatrist Katherine A. Halmi believes that this eating disorder stems from the ego, explaining that the severity of the core features of the disorder, including preoccupations with exercising, eating, weight and body image, forecast higher resistance to treatment.

The study was carried out by Dr. Walter Kaye at the School of Medicine in the University of San Diego. It involved a sample of 10 patients with anorexia.

The researchers discovered that one dose of COMP 360 brought about clinically significant reductions in the psychopathology of eating disorders in 30% of the patients, as observed at the one-month follow up. Researchers also observed that at the three-month follow up, 40% of the patients experienced clinically significant reductions.

Overall, the researchers note that 9 of the 10 subjects involved in the study found the psychedelic experience to be therapeutic and meaningful, adding that no severe adverse events were reported.

Compass Pathways chief medical officer, Dr. Guy Goodwin, stated that the study’s results offered promising evidence that the COMP 360 therapy could be beneficial to individuals with anorexia. He added that the company’s interest in the therapy’s potential to treat the disorder needed to be further studied in larger-scale clinical studies.

The data adds to a growing body of scientific exploration into this specific application of psilocybin. These findings were shared last month at the Society of Biological Psychiatry Annual Meeting.

Other research institutions, including the Imperial College London and Johns Hopkins University, are also recruiting patients with anorexia to take part in clinical trials evaluating the effectiveness of psilocybin in the treatment of this condition.

At the moment, no FDA-approved medical treatment exists for anorexia. However, prior research as well as the data from this new study suggests the potential for psychedelics in this space. For instance, a study conducted in 2017 involving individuals with eating disorders found that ayahuasca could be used to improve emotional regulation and symptoms of these disorders.

Meanwhile, Compass Pathways plans to continue exploring the effect of its psilocybin therapy in managing treatment-resistant depression in a phase III trial that will be launched soon.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.